6-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine | 92260-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine
• 英文别名: 6-bromo-1,2-dimethylimidazo[4,5-b]pyridine；6-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine；2,3-Dimethyl-6-bromo-4-aza-benzimidazole；2.3-Dimethyl-6-brom-4-aza-benzimidazol；6-bromo-2,3-dimethylimidazo[4,5-b]pyridine
• CAS: 92260-32-7
• 化学式: C₈H₈BrN₃
• mdl: MFCD08692134
• 分子量: 226.076
• InChiKey: ODPYZABMIQGXMO-UHFFFAOYSA-N

物化性质

• 熔点：
  108 °C
• 沸点：
  342.5±22.0 °C(Predicted)
• 密度：
  1.67±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 17.5h， 生成 (S)-ethyl 2-tert-butoxy-2-(7-(4-chlorophenyl)-2-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-6-yl)-5-methylbenzo[d]thiazol-6-yl)acetate
  参考文献：
  名称：

  THERAPEUTIC COMPOUNDS

  摘要：

  本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。

  公开号：

  US20130281433A1
• 作为产物：
  描述：

  5-溴-2-氯-3-硝基吡啶 在 盐酸 、 tin 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.5h， 生成 6-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  INHIBITORS OF HIV REPLICATION

  摘要：

  式(I)的化合物： 其中R1、R2、A1、A2、A3、A4、X和Y如本文所定义，可用作HIV复制抑制剂。

  公开号：

  US20100261714A1

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243528A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性麻痹; 以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩性侧索硬化或额颞叶痴呆。
• [EN] 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE LA 1H-IMIDAZO[4,5-C]QUINOLINONE
  申请人：NOVARTIS AG

  公开号：WO2010139731A1

  公开（公告）日：2010-12-09

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.

  该发明涉及在蛋白质和/或脂质激酶依赖性疾病的治疗中使用1H-咪唑并[4,5-c]喹啉酮衍生物及其盐，并用于制备用于治疗该等疾病的药物制剂；用于治疗蛋白质和/或脂质激酶依赖性疾病的1H-咪唑并[4,5-c]喹啉酮衍生物；一种治疗上述疾病的方法，包括向温血动物，特别是人类，施用1H-咪唑并[4,5-c]喹啉酮衍生物；包括1H-咪唑并[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新颖的1H-咪唑并[4,5-c]喹啉酮衍生物；以及制备新颖的1H-咪唑并[4,5-c]喹啉酮衍生物的方法。
• Halogenation of 2-Unsubstituted and 2-Methylimidazo[4,5-b]pyridine Derivatives
  作者：Yu. M. Yutilov、Kh. Ya. Lopatinskaya、N. N. Smolyar、S. V. Gres’ko

  DOI：10.1007/s11178-005-0186-y

  日期：2005.3

  Halogenation of 2-unsubstituted and 2-methylimidazo[4,5-b]pyridines and their N-methyl derivatives with bromine and chlorine in acetic acid takes different pathways, depending on the acetic acid concentration. The bromination in 50% aqueous acetic acid gives only 6-bromoimidazo[4,5-b]pyridines; bromination and chlorination of 2-unsubstituted imidazo[4,5-b]pyridines in glacial acetic acid leads to 5,6-dibromo(dichloro)imidazo[4,5-b]pyridin-2-ones, and bromination of 2-methylimidazo[4,5-b]pyridines in glacial acetic acid involves both the pyridine ring and the 2-methyl group to afford the corresponding 6-bromo-2-tribromomethylimidazo[4,5-b]pyridines.

  在乙酸中用溴和氯对 2-未取代的和 2-甲基咪唑并[4,5-b]吡啶及其 N-甲基衍生物进行卤化，根据乙酸浓度的不同，卤化途径也不同。在 50% 的乙酸水溶液中进行溴化反应只能得到 6-溴咪唑并[4,5-b]吡啶；在冰醋酸中对 2-未取代的咪唑并[4,5-b]吡啶进行溴化和氯化反应，可生成 5,6-二溴（二氯）咪唑并[4,5-b]吡啶-2-酮；在冰醋酸中对 2-甲基咪唑并[4,5-b]吡啶进行溴化反应，可生成 2-甲基咪唑并[4,5-b]吡啶-2-酮、2-甲基咪唑并[4,5-b]吡啶在冰乙酸中的溴化反应涉及吡啶环和 2-甲基，从而得到相应的 6-溴-2-三溴甲基咪唑并[4,5-b]吡啶。
• Therapeutic compounds
  申请人：Gilead Sciences, Inc.

  公开号：US08987250B2

  公开（公告）日：2015-03-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文提供了包括式I′的化合物及其盐。还提供了含有本文所披露的化合物的药物组合物，制备本文所披露的化合物的方法，用于制备本文所披露的化合物的中间体以及使用本文所披露的化合物治疗HIV感染的治疗方法。
• 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES
  申请人：Furet Pascal

  公开号：US20140005163A1

  公开（公告）日：2014-01-02

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone derivatives.

  本发明涉及使用1H-咪唑[4,5-c]喹啉酮衍生物及其盐治疗蛋白质和/或脂质激酶依赖性疾病，并用于制备治疗该类疾病的药物制剂；使用1H-咪唑[4,5-c]喹啉酮衍生物治疗蛋白质和/或脂质激酶依赖性疾病；一种治疗该类疾病的方法，包括向温血动物，特别是人类，给予1H-咪唑[4,5-c]喹啉酮衍生物；包含1H-咪唑[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新型1H-咪唑[4,5-c]喹啉酮衍生物；以及制备新型1H-咪唑[4,5-c]喹啉酮衍生物的方法。